Xencor Inc (XNCR)
AvoidA data-driven read of XNCR's strengths and risk factors, built from its financials, earnings history, analyst activity, and insider trading, not opinion or speculation.
Five independent market signals, analysts, institutions, insiders, short sellers, and price trend, each scored from real, current data. See exactly where the smart money agrees, and where it's split.
Signals are mixed: 3 of 5 available lean bullish, 2 lean bearish.
Every trading day in the last 2 years where XNCR moved 4% or more in a single session, most recent first, a quick read on how volatile this stock has really been. See full daily price history →
| Date | Move | Close |
|---|---|---|
| Aug 28, 2026 | -9.76% | $26.06 |
| Aug 24, 2026 | +4.30% | $29.00 |
| Aug 19, 2026 | +19.03% | $27.52 |
| Aug 12, 2026 | +4.89% | $23.18 |
| Aug 7, 2026 | +4.05% | $20.81 |
| Aug 3, 2026 | -4.01% | $19.40 |
| Jul 31, 2026 | -5.96% | $20.21 |
| Jul 30, 2026 | +10.04% | $21.49 |
| Jul 22, 2026 | -4.60% | $19.51 |
| Jul 21, 2026 | +8.72% | $20.45 |
| Jul 20, 2026 | +7.67% | $18.81 |
| Jul 17, 2026 | +16.86% | $17.47 |
| Jul 13, 2026 | -5.62% | $14.96 |
| Jul 8, 2026 | +5.04% | $16.46 |
| Jul 7, 2026 | +5.24% | $15.67 |
| Jul 1, 2026 | -4.47% | $15.38 |
| Jun 22, 2026 | +10.84% | $14.01 |
| Jun 17, 2026 | +4.75% | $12.78 |
| Jun 9, 2026 | +4.21% | $11.89 |
| Jun 4, 2026 | +5.17% | $12.01 |
| Jun 2, 2026 | -5.00% | $11.21 |
| May 20, 2026 | +8.74% | $11.32 |
| May 19, 2026 | -5.88% | $10.41 |
| May 15, 2026 | -5.56% | $11.22 |
| May 14, 2026 | -4.04% | $11.88 |
Showing the 25 most recent of 132 on record. Full history is on the Price Insights page.
Every major event from the past 12 months, earnings reports, insider transactions, and analyst upgrades or downgrades, merged into a single chronological feed so you can see what clustered together.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
465 North Halstead Street, Pasadena, CA, 91107, United States, 626 305 5900
Other Biotechnology companies tracked on this site, ranked by institutional ownership. Compare XNCR against its closest peers.
A complete statistical profile built from XNCR's full price, financial, and ownership history, not an isolated snapshot. Explore any category in depth below.